The anticancer activity of gefitinib is more significant in ST6Gal1-deficient CRC cells, as over-expressed ST6Gal1 was shown to suppress gefitinib-induced cytotoxic effects and promote gefitinib-mediated chemoresistance in CRC cells [5]. Here, ST6GAL1 is linked to colorectal carcinoma.